



JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015, Haryana (India)

October 23, 2024

The Department of Corporate Services- Listing
BSE Ltd,
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai-400 001
Scrip Code: 507789

The Department of Corporate Services- Listing
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E) Mumbai – 400 051
Symbol: JAGSNPHARM

Subject: Disclosure of Related Party Transaction under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 23(9) of the SEBI Listing Regulations, please find enclosed herewith disclosures of related party transactions in the revised format, as prescribed under SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated 22nd November 2021, for the half year ended commencing from April 1, 2024 to September 30, 2024.

We request you to take the above on record.

Thanking you,

For Jagsonpal Pharmaceuticals Limited

Abhishek Joshi Company Secretary & Compliance Officer

JAGSONPAL PHARMACEUTICALS LIMITED

Disclosure of related party transactions for the year ended Sep 30, 2024

(Rs. Lacs)

																		(Rs. Lacs)			
														Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
S. No	Details of the party (listed entity)	Details of the counterparty			Details of other related	Value of the related party transaction as	Remarks on approval by	Value of transaction during	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, intercorporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments							
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	party transaction	approved by the audit committee in Lakhs	audit committee	the reporting period in Lakhs	Opening balance	Closing balance	indebtednes s (loan/ issuance of debt/ any	Cost	Tenure	(loan/ advance/ inter- corporate	Interest Rate(%)	Tenure	Secured/ unsecured	which the funds will be utilised by the ultimate			
	1 Jagsonpal Pharmaceuticals Limited	Naari Pharma Pvt Ltd	Associates Company	Purchase of goods (RM)		5.10	Approved	5.10						- AVVVV 111							
	2 Jagsonpal Pharmaceuticals Limited	Naari Pharma Pvt Ltd	Associates Company	Purchase of goods (JW)		7.60	Approved	7.60													
	3 Jagsonpal Pharmaceuticals Limited	Naari Pharma Pvt Ltd	Associates Company	Sale of Service (Rent)		11.00	Approved	11.00													
	4 Jagsonpal Pharmaceuticals Limited	Aresko Lifesciences Pvt.Ltd.	Associates Company	Sale of Service (Rent)		1.20	Approved	1.20													
	5 Jagsonpal Pharmaceuticals Limited	Aresko Lifesciences Pvt.Ltd.	Associates Company	Purchase of goods (RM)		179.30	Approved	179.30													
	6 Jagsonpal Pharmaceuticals Limited	Ashish Lakhotia	KMP (CFO)	Remuneration		25.45	Approved	25.45													
	7 Jagsonpal Pharmaceuticals Limited	Abhishek Joshi	KMP (CS)	Remuneration		5.48	Approved	5.48													
	8 Jagsonpal Pharmaceuticals Limited	Manish Gupta	Managing Director	Remuneration		90.67	Approved	90.67													
	9 Jagsonpal Pharmaceuticals Limited	Debasis Bikas Nandy	Independent Director	Any other transaction	Director sitting fees	3.00	Approved	3.00													
1	O Jagsonpal Pharmaceuticals Limited	Radhika Madhukar Dudhat	Independent Director	Any other transaction	Director sitting fees	2.25	Approved	2.25													
1	1 Jagsonpal Pharmaceuticals Limited	Pallavi Dinodia Gupta	Independent Director	Any other transaction	Director sitting fees	2.75	Approved	2.75													